View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
The only drug approved by the Food and Drug Administration (FDA) to treat moderate to severe Alzheimer's disease (AD), memantine (Namenda) has shown a clear benefit for patients taking it in combination with donepezil, a cholinesterase inhibitor. In a randomized, double-blind, placebo-controlled clinical trial, researchers studied over 300 patients with moderate to severe AD receiving stable doses of donepezil plus either memantine or a placebo. Those in the memantine group had significantly better outcomes on measures of cognition, activities of daily living, global outcome (overall function), and behavior.
Approved by the FDA late last year, memantine is the first of a new class of drugs for AD. Because of its unique mechanism of action, it represents a new approach to treatment of late-stage AD.
"Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil," JAMA, P. Tariot, et al., January 21, 2004.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top